Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

US eosinophilic esophagitis market to reach $1.19 billion by 2030, forecasts GlobalData

The US eosinophilic esophagitis (EoE) market is projected to grow from $202 million in 2020 to $1.19 billion in 2030, registering a compound annual growth rate (CAGR) of 19.4%, driven by the transition from off-label therapies to FDA-approved, patient-friendly options such as Sanofi/Regeneron’s Dupixent (dupilumab), Takeda’s Eohilia (budesonide oral suspension), and Ellodi Pharmaceuticals’ late-stage pipeline […]
Read more

CRISPR-based therapeutics hold potential to combat AMR and cure chronic viral infections, says GlobalData

Clustered regularly interspaced short palindromic repeats (CRISPR)-based therapeutics are rapidly gaining traction for the management of infectious diseases. Programs targeting pathogens such as the human immunodeficiency virus (HIV), herpes simplex virus (HSV), and drug-resistant Escherichia coli (E. coli) are advancing in the clinic, signaling a transformative shift in the infectious disease space. CRISPR-based therapeutics show […]
Read more

Insmed’s pivotal win in bronchiectasis highlights potential of DPP-1 inhibitor in growing respiratory field, says GlobalData

Following the US FDA approval of Insmed’s Brinsupri for treatment of non-cystic fibrosis bronchiectasis (NCFB): Vinie Varkey, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “As the first-to-market therapy, Brinsupri (brensocatib) addresses the top unmet need for NCFB: an approved therapy that can reduce exacerbations and slow down the disease […]
Read more

AI improving idiopathic pulmonary fibrosis care, says GlobalData

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by the accumulation of scar tissue in the lungs, leading to respiratory failure and significantly impacting patients’ quality of life. Recent advancements in AI have emerged as a promising tool that can contribute to the management of IPF. AI algorithms that employ machine learning and […]
Read more

AbbVie’s upadacitinib holds potential to cement dominant place in alopecia areata with latest results, says GlobalData

AbbVie recently announced topline results from one of two parallel studies of the pivotal Phase III UP-AA trial evaluating upadacitinib in severe alopecia areata (AA). Upadacitinib’s latest results could provide AbbVie with a dominant place in AA while potentially addressing the need for treatment options with higher efficacy, according to GlobalData, a leading data and […]
Read more

Nanoscope Therapeutics’ MCO-010 holds potential to become new treatment option for retinitis, says GlobalData

Nanoscope Therapeutics has recently submitted a rolling biologics license application (BLA) to the FDA for MCO-010 (sonpiretigene isteparvovec), a novel gene therapy candidate targeting retinitis pigmentosa (RP). Currently, the RP treatment landscape includes only one FDA-approved therapy, Luxturna (voretigene neparvovec), which is indicated for a small subset of patients with biallelic RPE65 mutations. In contrast, […]
Read more

Unmet needs present persistent challenges for effective endometriosis treatment, says GlobalData

The endometriosis therapeutics market continues to face significant unmet needs, primarily due to low diagnosis rates, limited disease awareness, and a lack of well-tolerated, long-term treatment options. While surgical interventions can offer symptomatic relief, they are costly and do not guarantee long-term remission or prevention of recurrence. Moreover, patients often undergo multiple surgeries throughout their […]
Read more

Biomarker identification to address unmet needs of idiopathic pulmonary fibrosis treatment, says GlobalData

Idiopathic pulmonary fibrosis (IPF) is a progressive and often fatal lung disease characterized by the accumulation of scar tissue in the lungs, leading to respiratory failure. The current treatment approaches for IPF include Boehringer Ingelheim’s Ofev (nintedanib) and Roche’s Esbriet (pirfenidone). However, current treatments may not address several unmet needs in this space, particularly regarding […]
Read more

World Hepatitis Day 2025: Renewed global push urgent need amid rising mortality, says GlobalData

World Hepatitis Day, observed each year on 28 July, highlights the urgent need to combat viral hepatitis—one of the world’s deadliest infectious diseases, impacting over 300 million people globally. Despite available vaccines and treatments, rising mortality and persistent systemic, financial, and social barriers underscore the critical importance of renewed global efforts toward hepatitis elimination by […]
Read more

China’s obesity market poised for takeoff with homegrown therapies and late-stage pipeline, says GlobalData

China has recently approved the first locally developed obesity drug “Xinermei (mazdutide),” marking a critical milestone in the country’s obesity treatment landscape. Backed by a robust late-stage pipeline and differentiated dual-receptor mechanisms, the domestic obesity therapeutics market is set for rapid expansion, driven by innovation, rising disease burden, and a shift toward more accessible, locally […]
Read more

Diagnosed prevalent cases of HER2- breast cancer across 8MM set to reach 4.12 million in 2034, forecasts GlobalData

The burden of five-year diagnosed prevalent cases of HER2-Negative (HER2-) breast cancer is expected to increase at an annual growth rate (AGR) of 1.42% from around 3.61 million in 2024 to 4.12 million in 2034 across the eight major markets (8MM*), forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, “HER2-Negative Breast Cancer: […]
Read more

Semaglutide emerges as contender in cerebrovascular disease management, says GlobalData

Semaglutide, a GLP-1R agonist also known as Ozempic or Wegovy and initially developed for type 2 diabetes, is emerging as a promising candidate for neurological conditions. The recent clinical findings suggest its potential to improve outcomes in stroke and brain hemorrhage patients, driven by its cardiovascular and anti-inflammatory effects. These developments highlight a significant therapeutic […]
Read more
1 … 5 6 7 8 9 … 108